Skip to main content
KISQALI + Fulvestrant in 1L/2L Postmenopausal Patients

Majority of adverse reactions were transient, manageable, and reversible1-4

  • Infections included urinary and respiratory tract infections, gastroenteritis, and sepsis (1%)

  • Dose reductions due to ARs: 32% with KISQALI + fulvestrant

  • Permanent discontinuations: 8% with KISQALI + fulvestrant

  • Patients may require dose interruption, reduction, or discontinuation for adverse reactions. Monitoring should include: pulmonary symptoms, ECGs, serum electrolytes, LFTs, and CBCs. See Warnings and Precautions for risk of ILD/pneumonitis, SCARs, QT prolongation, hepatobiliary toxicity, neutropenia, and embryo-fetal toxicity

  • The most common ARs (reported at a frequency ≥20% on the KISQALI arm and ≥2% higher than placebo), including laboratory abnormalities: leukocytes decreased, neutrophils decreased, lymphocytes decreased, creatinine increased, hemoglobin decreased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, nausea, alanine aminotransferase increased, infections, platelets decreased, diarrhea, vomiting, constipation, glucose serum decreased, cough, rash, and pruritus

MONALEESA-3: ADVERSE REACTIONS OCCURRING IN ≥10% AND ≥2% HIGHER THAN PLACEBO. Please see full Prescribing Information for complete safety data.
MONALEESA-3: LABORATORY ABNORMALITIES. Please see full Prescribing Information for complete safety data.
Video thumbnail

Expert perspective on dosing and patient adherence in HR+/HER2- mBC

Dr Nick McAndrew shares his perspective on simple dose reductions with KISQALI and how to improve adherence in patients with HR+/HER2- mBC.
A guide for treating with KISQALI

KISQALI Treatment Guide

A guide to treating with KISQALI for your patients with HR+/HER2- metastatic breast cancer. Includes KISQALI overall survival data, as well as dosing, safety, and patient support.

1L=first line; 2L=second line; ALT=alanine aminotransferase; AR=adverse reaction; AST=aspartate aminotransferase; CBC=complete blood count; ECG=electrocardiogram; GGT=gamma-glutamyl transferase; ILD=interstitial lung disease; LFT=liver function test; mBC=metastatic breast cancer; SCAR=severe cutaneous adverse reaction.

References: 1. Kisqali [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. 3. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. 4. Data on file. Novartis Pharmaceuticals Corp; 2016.